5300S-12: S1115 pancreatic

SWOG 1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate and MK-2206 vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy

Type of Study
Cancer (Oncology) - Pancreas
Swedish Cancer Institute
Short Description

Purpose: This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to mFOLFOX therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy.

Temporarily Closed
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; patients with endocrine or neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible
  • Must have distant metastatic disease; patients with macroscopic residual disease post-resection as the only site of disease are not eligible; patients must not have clinically significant ascites or have brain metastases
  • Must have received one line, and no more than one line, of prior gemcitabine chemotherapy for pancreatic cancer; for patients who received treatment for advanced/metastatic disease, there must be documentation of disease progression while on this treatment; for patients who received chemotherapy for treatment in the adjuvant setting, recurrence to a metastatic site must be documented by imaging studies within 6 months of completing chemotherapy
  • Zubrod performance status of 0-1
  • Must be able to swallow tablets and capsules
  • Must not have received prior treatment with leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX), FOLFOX, MEK inhibitors, PI3K inhibitors, or AKT inhibitors.
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086